Orexo AB (publ)
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more
Orexo AB (publ) (ORXOF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.048x
Based on the latest financial reports, Orexo AB (publ) (ORXOF) has a cash flow conversion efficiency ratio of -0.048x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.60 Million) by net assets ($490.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Orexo AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Orexo AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Orexo AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orexo AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chian Hsing Forging Industrial Co Ltd
TWO:4528
|
0.041x |
|
Carlos Casado
BA:CADO
|
0.001x |
|
HAVRF
PINK:HAVRF
|
N/A |
|
Dhunseri Investments Limited
NSE:DHUNINV
|
-0.010x |
|
Genetec Technology Bhd
KLSE:0104
|
-0.110x |
|
World Known MFG (Cayman) Limited
TW:4581
|
0.041x |
|
Cyan AG
XETRA:CYR
|
0.046x |
|
Optivision Technology
TWO:3666
|
0.002x |
Annual Cash Flow Conversion Efficiency for Orexo AB (publ) (2015–2025)
The table below shows the annual cash flow conversion efficiency of Orexo AB (publ) from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $490.60 Million | $-195.40 Million | -0.398x | -115.41% |
| 2024-12-31 | $-126.30 Million | $-326.50 Million | 2.585x | +207.84% |
| 2023-12-31 | $58.90 Million | $-141.20 Million | -2.397x | -196.83% |
| 2022-12-31 | $193.90 Million | $-156.60 Million | -0.808x | -23.30% |
| 2021-12-31 | $349.60 Million | $-229.00 Million | -0.655x | -2277.60% |
| 2020-12-31 | $558.50 Million | $16.80 Million | 0.030x | -92.60% |
| 2019-12-31 | $706.40 Million | $287.00 Million | 0.406x | -20.07% |
| 2018-12-31 | $476.10 Million | $242.00 Million | 0.508x | +14.11% |
| 2017-12-31 | $329.10 Million | $146.60 Million | 0.445x | -11.51% |
| 2016-12-31 | $310.30 Million | $156.20 Million | 0.503x | +224.51% |
| 2015-12-31 | $270.10 Million | $-109.20 Million | -0.404x | -- |